Rigel Pharmaceuticals Inc (RIGL): EBITDA
$127.88M
Year ended 2025-12-31
$89.70M
Trailing 12 months to 2026-06-30
| Period ended | EBITDA | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $127.88M | +384.0% | 2026-03-03, From 2025-01-01 |
| 2024-12-31 | $26.42M | n/m | 2026-03-03, From 2024-01-01 |
| 2023-12-31 | -$19.25M | n/m | 2026-03-03, From 2023-01-01 |
| 2022-12-31 | -$54.55M | n/m | 2025-03-04, From 2022-01-01 |
| 2021-12-31 | -$11.33M | n/m | 2024-03-05, From 2021-01-01 |
| 2020-12-31 | -$28.27M | n/m | 2023-03-07, From 2020-01-01 |
| 2019-12-31 | -$68.41M | n/m | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | -$72.09M | n/m | 2021-03-02, From 2018-01-01 |
| 2017-12-31 | -$79.15M | n/m | 2020-02-27, From 2017-01-01 |
| 2016-12-31 | -$68.80M | n/m | 2019-02-28, From 2016-01-01 |
| 2015-12-31 | -$50.30M | n/m | 2018-03-06, From 2015-01-01 |
| 2014-12-31 | -$88.89M | n/m | 2017-03-07, From 2014-01-01 |
| 2013-12-31 | -$86.88M | n/m | 2016-03-08, From 2013-01-01 |
| 2012-12-31 | -$96.94M | n/m | 2015-03-03, From 2012-01-01 |
| 2011-12-31 | -$84.41M | n/m | 2014-03-04, From 2011-01-01 |
| 2010-12-31 | $36.63M | n/m | 2013-03-05, From 2010-01-01 |
| 2009-12-31 | -$110.63M | n/a | 2012-03-06, From 2009-01-01 |
EBITDA at similar companies
| Company | Year ended | EBITDA | Change YoY |
|---|---|---|---|
| Rigel Pharmaceuticals Inc (RIGL) | 2025-12-31 | $127.88M | +384.0% |
| Rapport Therapeutics, Inc. (RAPP) | 2025-12-31 | -$124.08M | n/m |
| Ardelyx, Inc. (ARDX) | 2025-12-31 | -$37.92M | n/m |
| Olema Pharmaceuticals, Inc. (OLMA) | 2025-12-31 | -$178.21M | n/m |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | -$191.52M | n/m |
| Enliven Therapeutics, Inc. (ELVN) | 2025-12-31 | -$119.36M | n/m |
| Standard Biotools Inc. (LAB) | 2025-12-31 | -$100.99M | n/m |
| Geron Corp (GERN) | 2025-12-31 | -$68.11M | n/m |
| Biohaven Ltd. (BHVN) | 2025-12-31 | -$735.46M | n/m |
Compare RIGL, RAPP, ARDX, OLMA side by side · Screen every company in Pharmaceutical Preparations ↗